Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Genet Dev. 2011 Feb;21(1):29-33. doi: 10.1016/j.gde.2010.12.002. Epub 2011 Jan 12.

Mutant onco-proteins as drug targets: successes, failures, and future prospects.

Author information

  • Helen Diller Family Comprehensive Cancer Center, UCSF, 1450 3rd Street, Room 371, Box 0128, San Francisco, CA 94158, USA. mccormick@cc.ucsf.edu

Abstract

Mutant onco-proteins play a direct, causal role in cancer and are therefore considered attractive drug targets. Clinical experience has supported this view, with some exceptions. However, clinical benefit has often been restricted by rapid emergence of drug-resistant clones through several distinct mechanisms. This problem can, in principle, be addressed through cocktails containing several drugs. However, the number of tumors whose survival is dependent on a single, druggable mutant onco-protein is currently unknown. The majority of tumors may be driven either by single drivers that are un-druggable, or by combinations of drivers. In both cases, new approaches will be necessary. Development of systemic RNA interference may be a solution to these problems.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID:
21236660
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk